Recent Progress in Individualized Therapy of Colorectal Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

张洪伟 , 同李平 , 孙力

Corresponding author：

Keywords：

结直肠癌; 个体化治疗; 术前评估; 手术方式; 辅助化疗

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

结直肠癌是一种严重威胁我国国民生命的恶性肿瘤，近年来其发病率呈不断上升的趋势。根据WHO报告的资料［1］显示，我国结直肠癌死亡率2005年比1991年增加70.7%，年均增加4.71%。尽管对结直肠癌的病因学研究和以手术切除、放射治疗和化学药物治疗为主的综合治疗取得了一定进展，但结直肠癌的治疗仍然面临巨大挑战。对不同个体采用相同的治疗方案不仅不能提高治疗效果，而且造成医疗资源的浪费，甚至给患者带来伤害。目前，个体差异与疗效的关系越来越受到临床医生和研究者的重视。随着循证医学的不断发展，结直肠癌的个体化治疗日益成为临床治疗及基础研究的重点。结直肠肿瘤多学科协作(multidisciplinary team，MDT)诊治模式的运用为结直肠癌个体化诊治提供了新的平台［2］。....................

Citation： 张洪伟,同李平,孙力. Recent Progress in Individualized Therapy of Colorectal Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2009, 16(9): 689-692. doi: Copy

1.	郑树主编. 结直肠肿瘤—基础研究与临床实践 [M]. 北京: 人民卫生出版社， 2006: 3-4.
2.	Kelly MJ, Lloyd TD, Marshall D, et al. A snapshot of MDT working and patient mapping in the UK colorectal cancer centres in 2002 [J]. Colorectal Dis, 2003; 5(6): 577-581.
3.	de Geus-Oei LF, Vriens D, van Laarhoven HW, et al. Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review [J]. J Nucl Med, 2009; 50 Suppl 1: 43S-54S.
4.	Geus-Oei LF, Oyen WJ. Predictive and prognostic value of FDG-PET [J]. Cancer Imaging, 2008; 8: 70-80.
5.	Savides TJ, Master SS. EUS in rectal cancer [J]. Gastrointest Endosc, 2002; 56(4 Suppl): S12-S18.
6.	Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089 [J]. J Clin Oncol, 2003; 21(15): 2912-2919.
7.	万德森. 结直肠癌外科治疗若干热点问题 [J]. 中华肿瘤防治杂志, 2007; 14(8): 561.
8.	Burghardt J, Buess G. Transanal endoscopic microsurgery (TEM): a new technique and development during a time period of 20 years [J]. Surg Technol Int, 2005; 14: 131-137.
9.	Saha S, Dan AG, Viehl CT, et al. Sentinel lymph node mapping in colon and rectal cancer: its impact on staging, limitations, and pitfalls [J]. Cancer Treat Res, 2005; 127: 105-122.
10.	Simunovic M, Smith AJ, Heald RJ. Rectal cancer surgery and regional lymph nodes [J]. J Surg Oncol, 2009; 99(4): 256-259.
11.	Moriya Y. Selection and techniques of surgical procedures based on the mode of cancer spread of rectal cancer [J]. Nippon Geka Gakkai Zasshi, 2005; 106(4): 302-305.
12.	VanMeter A, Signore M, Pierobon M, et al. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine [J]. Expert Rev Mol Diagn, 2007; 7(5): 625-633.
13.	Speer R, Wulfkuhle J, Espina V, et al. Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy [J]. Cancer Genomics Proteomics, 2007; 4(3): 157-164.
14.	崔恒官, 曹秀峰. 手术为主的大肠癌综合治疗 [J]. 世界华人消化杂志, 2008; 16(16): 1774-1780.
15.	Yu J, Shannon WD, Watson MA, et al. Gene expression profiling of the irinotecan pathway in colorectal cancer [J]. Clin Cancer Res, 2005; 11(5): 2053-2062.
16.	Bandrés E, Zárate R, Ramirez N, et al. Pharmacogenomics in colorectal cancer: the first step for individualized-therapy [J]. World J Gastroenterol, 2007; 13(44): 5888-5901.
17.	Pohl A, Lurje G, Manegold PC, et al. Pharmacogenomics and -genetics in colorectal cancer [J]. Adv Drug Deliv Rev, 2009; 61(5): 375-380.
18.	Paoluzzi L, Singh AS, Price DK, et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38 [J]. J Clin Pharmacol, 2004; 44(8): 854-860.
19.	Marchetti P, Galla DA, Russo FP, et al. Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line [J]. Anticancer Res, 2004; 24(1): 219-226.
20.	Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy [J]. J Clin Oncol, 2001; 19(23): 4298-4304.
21.	Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy [J]. J Clin Oncol, 2007; 25(10): 1247-1254.
22.	Funke S, Brenner H, Chang-Claude J. Pharmacogenetics in colorectal cancer: a systematic review [J]. Pharmacogenomics, 2008; 9(8): 1079-1099.
23.	Argyriou AA, Kalofonos HP. Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumours [J]. Mol Med, 2009; 15(5-6): 183-191.
24.	Kim JS, Kim JM, Li S, et al. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy [J]. Int J Radiat Oncol Biol Phys, 2006; 66(1): 195-200.
25.	Chang DZ, Kumar V, Ma Y, et al. Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy [J]. J Hematol Oncol, 2009; 2: 18.
26.	Van Cutsem E, Lang I, D’haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience [J]. J Clin Oncol, 2008; 26 (May 20 Suppl, Abstr 2).
27.	Bokemeyer C, Bondarenko I, Hartmann JT, et al. Korale-wski, KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience [J]. J Clin Oncol, 2008; 26(May 20 Suppl; Abstr 4000).

1. 郑树主编. 结直肠肿瘤—基础研究与临床实践 [M]. 北京: 人民卫生出版社， 2006: 3-4.
2. Kelly MJ, Lloyd TD, Marshall D, et al. A snapshot of MDT working and patient mapping in the UK colorectal cancer centres in 2002 [J]. Colorectal Dis, 2003; 5(6): 577-581.
3. de Geus-Oei LF, Vriens D, van Laarhoven HW, et al. Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review [J]. J Nucl Med, 2009; 50 Suppl 1: 43S-54S.
4. Geus-Oei LF, Oyen WJ. Predictive and prognostic value of FDG-PET [J]. Cancer Imaging, 2008; 8: 70-80.
5. Savides TJ, Master SS. EUS in rectal cancer [J]. Gastrointest Endosc, 2002; 56(4 Suppl): S12-S18.
6. Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089 [J]. J Clin Oncol, 2003; 21(15): 2912-2919.
7. 万德森. 结直肠癌外科治疗若干热点问题 [J]. 中华肿瘤防治杂志, 2007; 14(8): 561.
8. Burghardt J, Buess G. Transanal endoscopic microsurgery (TEM): a new technique and development during a time period of 20 years [J]. Surg Technol Int, 2005; 14: 131-137.
9. Saha S, Dan AG, Viehl CT, et al. Sentinel lymph node mapping in colon and rectal cancer: its impact on staging, limitations, and pitfalls [J]. Cancer Treat Res, 2005; 127: 105-122.
10. Simunovic M, Smith AJ, Heald RJ. Rectal cancer surgery and regional lymph nodes [J]. J Surg Oncol, 2009; 99(4): 256-259.
11. Moriya Y. Selection and techniques of surgical procedures based on the mode of cancer spread of rectal cancer [J]. Nippon Geka Gakkai Zasshi, 2005; 106(4): 302-305.
12. VanMeter A, Signore M, Pierobon M, et al. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine [J]. Expert Rev Mol Diagn, 2007; 7(5): 625-633.
13. Speer R, Wulfkuhle J, Espina V, et al. Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy [J]. Cancer Genomics Proteomics, 2007; 4(3): 157-164.
14. 崔恒官, 曹秀峰. 手术为主的大肠癌综合治疗 [J]. 世界华人消化杂志, 2008; 16(16): 1774-1780.
15. Yu J, Shannon WD, Watson MA, et al. Gene expression profiling of the irinotecan pathway in colorectal cancer [J]. Clin Cancer Res, 2005; 11(5): 2053-2062.
16. Bandrés E, Zárate R, Ramirez N, et al. Pharmacogenomics in colorectal cancer: the first step for individualized-therapy [J]. World J Gastroenterol, 2007; 13(44): 5888-5901.
17. Pohl A, Lurje G, Manegold PC, et al. Pharmacogenomics and -genetics in colorectal cancer [J]. Adv Drug Deliv Rev, 2009; 61(5): 375-380.
18. Paoluzzi L, Singh AS, Price DK, et al. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38 [J]. J Clin Pharmacol, 2004; 44(8): 854-860.
19. Marchetti P, Galla DA, Russo FP, et al. Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line [J]. Anticancer Res, 2004; 24(1): 219-226.
20. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy [J]. J Clin Oncol, 2001; 19(23): 4298-4304.
21. Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy [J]. J Clin Oncol, 2007; 25(10): 1247-1254.
22. Funke S, Brenner H, Chang-Claude J. Pharmacogenetics in colorectal cancer: a systematic review [J]. Pharmacogenomics, 2008; 9(8): 1079-1099.
23. Argyriou AA, Kalofonos HP. Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumours [J]. Mol Med, 2009; 15(5-6): 183-191.
24. Kim JS, Kim JM, Li S, et al. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy [J]. Int J Radiat Oncol Biol Phys, 2006; 66(1): 195-200.
25. Chang DZ, Kumar V, Ma Y, et al. Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy [J]. J Hematol Oncol, 2009; 2: 18.
26. Van Cutsem E, Lang I, D’haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience [J]. J Clin Oncol, 2008; 26 (May 20 Suppl, Abstr 2).
27. Bokemeyer C, Bondarenko I, Hartmann JT, et al. Korale-wski, KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience [J]. J Clin Oncol, 2008; 26(May 20 Suppl; Abstr 4000).

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Recent Progress in Individualized Therapy of Colorectal Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content